CSIMarket Company Name, Ticker, Competitors, else..
 
Lineage Cell Therapeutics Inc   (NYSE: LCTX)
Other Ticker:  
 
 
Price: $0.4298 $0.02 3.842%
Day's High: $0.4386 Week Perf: -8.51 %
Day's Low: $ 0.40 30 Day Perf: -13.07 %
Volume (M): 0 52 Wk High: $ 1.40
Volume (M$): $ 0 52 Wk Avg: $0.79
Open: $0.41 52 Wk Low: $0.37



 Market Capitalization (Millions $) 89
 Shares Outstanding (Millions) 207
 Employees 201
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 1

Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company that focuses on developing and commercializing novel cell therapies for the treatment of degenerative diseases. The company's technology platform involves the use of pluripotent stem cells to create cell-based therapies to restore or replace damaged cells in the body. Lineage Cell Therapeutics is primarily focused on developing treatments for conditions such as age-related macular degeneration, spinal cord injuries, and osteoarthritis. The company's goal is to improve the quality of life for patients by providing innovative and effective treatment options.


   Company Address: 2173 Salk Avenue Carlsbad 92008 CA
   Company Phone Number: 287-8990   Stock Exchange / Ticker: NYSE LCTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALBT      % 
BCDA        2.5% 
BPSR   -1.64%    
ONVO        17.2% 
TIL        14.88% 
VCEL        14.88% 
• View Complete Report
   



Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc's Trailblazing Journey: Overcoming a Surprising $-0.04 per Share Loss Amidst the Fiscal Time-frame Ending September 30, 2023



As the fiscal year for Lineage Cell Therapeutics Inc comes to a close, the company's financial results paint a challenging picture. With losses per share increasing and revenue taking a significant hit, the past year has undoubtedly been a tough one for the biotechnology firm. However, despite these setbacks, there are signs of hope as the market responds positively and the stock shows some upward momentum.
Losses and Revenue Decline:
The financial results for the period ending September 30, 2023, depict a continued struggle for Lineage Cell Therapeutics Inc. The company experienced a loss of $-0.04 per share, a stubborn repetition of the previous year's loss. Moreover, the loss widened from $-0.03 per share from the previous quarter, indicating a concerning trend.
Lineage Cell Therapeutics Inc

Demanding Quarter for Lineage Cell Therapeutics Inc as Deficit Increases Due to Declining Demand

Declining Demand Causes Increase in Deficit for Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc, a leading company in the biotechnology industry, recently released its financial report for the second quarter of 2023. The report highlighted a concerning increase in deficit, which was primarily attributed to a decline in demand for their products. This news has raised concerns among shareholders and investors.
According to the report, Lineage Cell Therapeutics Inc's deficit per share inched up to $-0.03 from $-0.04 compared to the previous year. This slight increase is a reflection of the challenging market conditions the company has been facing. The company's revenue also plummeted by -29.168%, dropping from $4.55 million to $3.23 million in the same reporting period. This decline in revenue is a significant setback for Lineage Cell Therapeutics Inc, as it signifies a considerable decrease in customer demand.
Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc Experiences Significant Improvement in Financial Performance, Reducing Deficit and Progressing in Return on Investment (ROI) Ranking

Lineage Cell Therapeutics Inc, a Healthcare company, reported a cumulative net loss of $-24 million during the 12 months ending in the first quarter of 2023. This resulted in a negative return on investment (ROI) of -22.85%. Interestingly, within the Healthcare sector, 316 other companies had a higher return on investment.
However, there is some positive news for Lineage Cell Therapeutics Inc. The return on investment, overall ranking has progressed in the Mar 31 2023 quarter, so far to 2947 from the total ROI ranking in the fourth quarter of 2022 at 3930. In addition, for the most recent fiscal period, the company decreased a loss per share of $-0.03 per share compared to $-0.04 a year prior. EPS also improved from $-0.04 per share from the prior financial reporting period.






Lineage Cell Therapeutics Inc's Segments
Upfront License Fees    89.6 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com